UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used to treat hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). This study aimed to capture the real-world efficacy and tolerability of CDK 4/6is. Patient...

Celý popis

Podrobná bibliografie

Hlavní autoři:	G. Gullick, C.N. Owen, W.J. Watkins, S. Cook, J. Helbrow, H. Reed, R. Squires, S. Park, E. Weir, F. Aquilina, N. Webber, E. Nye, C. Atkinson, C. Blair, A. Halstead, E. Daniels, A. Alves, S. Chew, W. Thomas, S. Spensley, M. Beresford, R. Bowen, T. Robinson
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-09-01
Edice:	ESMO Real World Data and Digital Oncology
Témata:	HR+/HER2− locally advanced and metastatic breast cancer cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) real-world evidence efficacy survival data toxicity
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2949820124000420
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!